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Abstract 
In facial reconstructive surgery, new techniques based on the principles of tissue engineering 
have moved over the last decade from the bench closer to the bed side, where they are 
being combined with the principles of plastic surgery. In particular, mechanically competent 
cartilage grafts and osteoinductive constructs vascularized by flaps are envisioned to replace 
autologous or alloplastic materials, with the goal to reduce donor site morbidity and to 
increase graft durability. Here we provide an overview of typical surgical procedures in facial 
reconstructive surgery and summarize how advances in cartilage and bone tissue 
engineering might replace and improve current treatments. 
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Introduction 
Trauma, cancer or congenital abnormalities often lead to cartilaginous and bony 
defects in the head and neck region. These tissue losses can either be replaced by tissue 
transfer from a healthy site (autografts) or by non-biological materials (alloplastic implants). 
Autologous tissue reconstruction is limited by the availability of donor tissue, morbidity at the 
donor site, time consuming surgery and mismatch of mechanical properties. Alloplastic 
implants (stainless steel, Dacron, polyacrylates, etc.) are readily available and do not lead to 
donor site morbidity, but they are not long lasting and are associated with a high rate of 
complications, such as infection, chronic irritation and sometimes even carcinogenicity. 
Therefore autologous implants remain the prevalent and also most versatile option in facial 
reconstructive surgery.  
A possible solution for providing sufficient amounts of tissue without the downsides of 
autologous transplants or alloplastic implants would be to engineer tissues which meet the 
requirements of the repair site, starting from the patient’s own cells. In general, the goals of 
engineering bone and cartilage in the head and neck area are (i) to achieve similar or even 
better results as compared to traditional reconstructive techniques and (ii) to avoid the 
concomitant and sometimes considerable donor site morbidity.  
The purpose of this article is to give an overview of some surgical procedures in 
reconstructive surgery of the head and neck, and describe how Tissue Engineering 
approaches can replace and improve current treatments. 
 
Clinical need of cartilage 
Cartilage is widely distributed throughout the human body and is comprised of 
chondrocytes embedded in an extracellular matrix composed primarily of proteoglycans, 
collagen, and water. Cartilage is a relatively simple but highly specialized connective tissue, 
which has no internal vascular network and possesses limited ability for repair and 
regeneration: injury or resection generally results in scar formation, leading to permanent 
loss of structure and function. Cartilage can be divided into categories according to the 
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composition of the matrix and its biological role in the body. Hyaline cartilage, which is rich in 
type II collagen, can be found in ribs, trachea, nose and articulating surfaces of bones. 
Elastic cartilage, which contains large amounts of elastin, is found in tissues such as the 
external ear, the epiglottis, and portions of the larynx. Fibrocartilage, which is rich in type I 
collagen, can be found as part of the lower and upper lid, menisci, intervertebral disc and in 
certain ligaments and tendons. Since cartilage nutrition is not from a vascular network, the 
tissue can be surgically transferred to repair sites with high versatility. 
 
The state of the art of reconstruction 
Shape and function of the nose, ear and eyelid derives from the embedding of hyaline, 
elastic or fibrocartilage between an epithelial layer and a skin layer. The reconstruction of 
multilayer defects in these tissues due to trauma, tumor [1] or congenital deformities (e.g., 
microtia) may be viewed as one of the most technically demanding procedures in facial 
plastic surgery. Despite past attempts of using alloplastic materials, the use of autologous 
cartilage, generally harvested from unaffected sites and shaped to the desired form, marks 
the golden standard for functional or aesthetic recovery.  
In reconstruction of multilayer defects of the nasal wall and tip, the combination of various 
local flaps and autologous cartilage, typically from the nasal septum or the ear, is the basis 
for high stability, sufficient function and proper three-dimensional shape [2]. Figure 1 
illustrates a typical case for the reconstruction of the ala of the nose following tumor 
resection. After resection of the tumor (Fig 1a), a mucosal flap for innerlining was created 
(Fig 1b). A septal cartilage graft was harvested, shaped according to the defect (Fig 1c) and 
secured in the repair site by resorbable sutures (Fig 1d). The entire construct was then 
covered with a forehead flap and after 4 months resulted in structural and functional 
reconstruction (Fig. 1e). As an alternative to septal cartilage combined with a local flap, an 
auricular composite tissue consisting of skin and underlying cartilage can be used for grafting 
[3;4]. The reconstruction of large defects of the lower or upper lid is similar in concept to the 
nose reconstruction. The possible donor sites for the cartilage graft are the ear or the nasal 
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septum [5]. Different reconstruction concepts are available for the complex three-dimensional 
structure of the ear, depending on defect size and location [6]. Cartilage grafts are usually 
required in two or three layer defects located to the helix and anthelix, whereas cartilaginous 
defects of the concha can be adequately resurfaced with skin flaps if the cartilage framework 
of the helix and anthelix is preserved. Cartilage donor sites include the ear cartilage itself 
from the ipsi- or contralateral ear, the nasal septum or rib. In cases of subtotal or total 
absence of the auricle, complete cartilage framework reconstruction has to be carried out 
using as much as the cartilaginous part of three ribs [7-9]. Soft tissue coverage is provided 
by using either local skin or a superficial temporoparietal fascial flap. 
Donor site morbidity 
Harvesting cartilage from ear, nasal septum or rib in reconstruction of multilayer defects of 
the nose, eyelid or ear can lead to several complications. Haematoma, wound infection, skin 
necrosis, cicatricial deformity but also fulminant chondritis with loss of major parts of ear and 
septum cartilage or thorax deformity have been described.  
 
Clinical need of bone 
The bone structure in the head 
In mammalians, two different principles of bone development have to be considered: the 
indirect and the direct pathway of bone formation. The indirect or endochondral ossification is 
based on the differentiation of mesenchymal progenitor cells (MPC) into cartilage, followed 
by mineralization and replacement of this cartilage by bone matrix produced by osteoblasts. 
The direct or intramembranous ossification is initiated by clusters of MPC which differentiate 
directly into metabolically active osteoblasts. During skeletal development, every load 
bearing long bone is formed by endochondral ossification, whereas intramembranous 
ossification is responsible for bone formation in the head, including the clavicles.  
Due to acting forces in the head and neck area, the facial skeleton is mainly composed of 
very dense cortical bone. The spongeous part, providing vascularization in long bones, is 
reduced to a minimum (mandible) or even not existing (malar complex, facial wall of the 
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maxillary sinus). As a consequence, the periosteum plays an important role in the 
vascularization of the facial skeleton [10]. This different type of vascularization, as compared 
to long bones, favours the incorporation of a non-vascularized, free bone graft, provided 
sufficient amount of soft tissue in the recipient bed.  
 
The state of the art of reconstruction 
Skeletal defects in the head and neck region arise from trauma, infection, tumor 
resection or abnormal congenital pathologies. These defects, depending on their size, can 
either be reconstructed by free bone grafts harvested from the skull [11], the iliac crest or the 
proximal tibia, or by vascularized tissue grafts using the fibula, scapula and iliac crest [12;13]. 
The method of  free vascularized tissue transfer using microsurgical techniques has become 
a reliable procedure during the past few years [14]. In case of reconstruction of a whole jaw, 
bone as well as soft tissue has to be regenerated. The preformation of the vascularized 
fibular graft, together with simultaneous placement of dental implants, offers an elegant 
method of immediate prosthetic rehabilitation of the patient, but requires meticulous planning 
of the operative and reconstructive treatment [15]. The two-stage operating procedure, 
recently reported [16], is now illustrated in more details in Figure 2. Prior to implant 
placement during the first stage, the future implant position and the position of the graft are 
planned on plaster models (Fig. 2a). Utilizing a drilling template with additional gauge (Fig 
2b), the implants can be inserted perpendicularly to the surface of the fibular graft providing 
straight preparation of the drill hole through the bicortical bone. The fibula and the implants 
are then covered with a split skin graft which has to be isolated against ingrowth of soft 
tissues by a Gore-Tex® membrane. Six weeks after the first stage procedure, the implants 
are uncovered and the original drilling template can be applied to perform the planned 
osteotomies (Fig 2c). After abutment-connection, the bar is fixed to the osteotomized graft 
and the prostheses attached to the bar construction (Fig 2c). The bar borne prosthesis 
together with the fibular graft are shaped and fixed to the recipient bed and finally 
microsurgical connection of the vessels is accomplished. This type of reconstruction allows 
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immediate prosthetic rehabilitation after the second operative step (Fig 2d). Alternatively, the 
vascularized grafts may be harvested from different areas (e.g., iliac crest, scapula), 
depending on the morphology of the defect and the type of intended reconstruction [17].  
Donor site morbidity 
 
Every harvesting procedure gives rise to donor site morbidity. The morbidity may be 
limited to postoperative pain but, depending on the amount of bone needed and the 
harvesting site, wound healing disturbances, chronic pain and even functional impairment 
can occur. Donor site morbidity can either be analysed subjectively (pain, loss of sensibility) 
or objectively by assessing clinical or functional parameters (e.g., ankle instability, gait 
analysis). The iliac crest and the fibula are the most commonly used donor sites in bone 
regeneration. Donor site morbidity after harvesting bone from the iliac crest is considered 
low, and severe complications like fractures or large haematoma are rarely observed [18]. 
Patient perception of morbidity after harvesting a fibular graft is low [19], however complaints 
like pain, feeling of ankle instability and inability to run are frequently mentioned.  Moreover, 
functional tests revealed gait disturbances as compared to healthy individuals. These 
findings suggest that, although the morbidity after harvesting a fibular graft is subjectively 
considered low, the reautomatization of gait may be affected among patients.  
Possible applications of osteoconductive materials in the head and neck area 
 
Osteoconductive materials have been introduced in the reconstructive surgery of 
bone since many years. Depending on the size and morphology of a given defect, either 
small granulates or custom-made constructs are needed. Small osteoconductive granulates, 
alone or in combination with autologous bone chips, can be used in almost every bone 
regeneration procedure in oral surgery. The additional application of a biodegradable and 
semipermeable membrane [20] prevents ingrowth of scar tissue and allows locally existing  
MPC to develop into bone forming osteoblasts (Fig 3 a, b). A very common indication for the 
use of small granulates is the sinus elevation procedure [21] in order to regenerate bone in 
the vertical dimension, prior or together with implant placement in the upper jaw (Fig 3c). 
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Large defects of the skull, the facial skeleton (Fig 4a) or the jaws have to be regenerated by 
three dimensional scaffolds which have to fit exactly into a given defect. After performing 
computed tomography,  a three dimensional model of the facial skeleton including the defect 
can be manufactured (Fig 4b) and finally the scaffold to be used intraoperatively may be 
produced by rapid prototyping techniques [22]. However, due to the typically large size of the 
defects, in these cases bone regeneration would require combination of the custom-made 
osteoconductive scaffold with either osteogenic growth factors or autologous osteoprogenitor 
cells, in order to generate an osteoinductive graft (see chapter Tissue engineering of bone). 
 
Tissue engineering of cartilage 
The goal of cartilage tissue engineering in facial reconstructive surgery is to generate 
a graft which can be implanted at different sites of the head and neck by applying the same 
surgical techniques as in reconstruction using autologous grafts. Engineering of a cartilage 
graft would start from obtaining a small biopsy from the nasal septum, ear or rib cartilage. 
This procedure can be performed under local anaesthetic in a minimally invasive fashion, 
and will not lead to donor site morbidity, as for the harvest of large grafts for reconstructive 
purposes. After enzymatic digestion of the specimen, the cells would be expanded in vitro 
and then induced to grow on bioactive degradable scaffolds that provide the structural and 
biochemical cues to guide their differentiation and generate a three-dimensional (3D) tissue. 
Such construct would then be transplanted into the defect, where further cell differentiation 
and tissue integration is expected to occur (Fig 5). 
 
Cell sources 
External ear [23;24] and nasal [25-27] chondrocytes have been used with various 
degrees of success to engineer in vitro and/or in vivo 3D cartilaginous tissues. Taking both 
cell yields and proliferation rates into account, we recently reported that a biopsy of human 
ear, nasal or rib cartilage and weighing a few milligrams, would yield tens of millions of cells 
over a 2-3 week period [28]. This number of cells, based on reported seeding densities of 
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non-articular chondrocytes into various 3D scaffolds [23;29], would be sufficient for the 
generation of autologous grafts of clinically relevant size (i.e., greater than 1 cm2 in size). But 
the key point is the chondrogenic capacity of these cells, as chondrocytes during monolayer 
expansion de-differentiate to a fibroblastic stage. Although in principle re-differentiation can 
be achieved upon transfer into a 3D culture environment [30], the potential of human 
expanded chondrocytes to re-differentiate and generate a functional matrix is limited [31] and 
decreases with donor age [32]. To overcome these limitations, specific regulatory molecules 
(e.g., growth factors, hormones, metabolites) have been employed as medium supplements 
during the different culture phases. Results indicate that expansion of chondrocytes in the 
presence of growth factors not only increases the cell proliferation rate, but also maintains 
the ability of the cells to re-differentiate upon transfer into a 3D environment [33;34] and to 
subsequently respond to differentiating agents [35]. At present, however, in literature we 
could not find a comparative animal or clinical study concerning the use of chondrocytes 
expanded under conditions favouring cell proliferation and maintenance of chondrogenic 
ability.  
An alternative to the use of differentiated chondrocytes is the use of cells with chondrogenic 
differentiation capacity, like mesenchymal progenitor cells (MPC). MPC can be isolated for 
instance from bone marrow aspirates and have the potential to differentiate into various 
mesenchymal tissue lineages [36]. Despite the reports that MPC can generate cartilaginous 
tissues [37;38], the molecules expressed indicate possible instability of the cartilage 
phenotype, associated with remodelling of the engineered cartilage into a mineralized tissue. 
Moreover, no report has been published so far regarding the pre-clinical or clinical use of 
MPC in facial cartilage reconstruction.  
 
Three-dimensional scaffolds 
Another critical element in engineering cartilage is a suitable scaffold that displays biological 
and physical properties matching both the needs of differentiating chondrocytes in vitro and 
of regenerating cartilage in vivo [39]. The scaffold must provide sufficient mechanical 
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strength and stiffness to substitute initially for wound contraction forces, and later for the 
remodelling of the tissue. Furthermore, it should enhance cell attachment and provide 
enough space to allow the exchange of nutrients and waste products and the deposition of 
extracellular matrix. In addition, the mechanical characteristics of the scaffold should be 
such, that at the time of implantation the cell-scaffold construct can sustain the surgical 
manipulation and the insertion of sutures.  
Different research groups have used a wide variety of scaffolds in the attempt to generate 
cartilaginous tissues in vitro. The form and composition of these scaffolds range from non-
woven meshes and foams of alpha-hydroxypolyesters [37;40;41], polyglactin [42] or 
hyaluronan alkyl esters [43;44] to photo-crosslinked hydrogels [45;46] and sponges based on 
different types of collagen and glycosaminoglycans [47;48]. Composites consisting of a 3D 
porous scaffold filled with cells embedded in a fibrin or alginate gel have also been explored. 
But many of these scaffolds are still in the experimental evaluation and several issues still 
have to be addressed, related to the interactions between cells and specific substrates, the 
influence of the pore size distribution on cell behaviour and the effect of scaffold geometry 
(i.e., in the form of a foam, mesh or gel) on the induction/maintenance of the chondrocytic 
phenotype.  
Upscaling of the constructs 
 
One of the major challenges in cartilage tissue engineering is the generation of 
uniform tissues of clinically relevant size (i.e., a few square centimeters in area and 3-4 mm 
in thickness). An upscaling of the constructs could be reached by the use of bioreactors, 
where cell seeding and culture may be facilitated by the application of mechanical and/or 
hydrodynamic forces [49]. Bioreactors would also provide a controlled in vitro environment 
over specific biochemical and physical signals, which have the potential to regulate 
chondrogenesis and improve the structure and function of the resulting cartilage tissues [50-
54]. Despite the great efforts currently dedicated to the development and use of bioreactors 
for the engineering of functional cartilage tissue, it is still rather unclear which specific 
physical stimulation regime is required to induce a specific effect on cultured chondrocytes.  
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 Tissue engineering of bone 
The goal of bone tissue engineering in facial reconstructive surgery is to generate an 
osteoinductive graft, namely a construct which upon implantation in the area to be 
reconstructed is capable to initiate the formation of bone tissue. Engineering of an 
osteoinductive graft of predefined size and shape can be achieved by loading a 3D scaffold 
with either osteogenic cells or bone morphogenetic proteins. According to the former 
approach, osteogenic cells are obtained from biopsies of diverse possible tissues (e.g., bone 
marrow, periosteum) and are typically expanded in culture. The latter approach appears 
more simple, since it does not require ex vivo cell processing, but opens the biological 
question of how the overdose of one single molecule could recapitulate the complex set of 
molecular events physiologically involved in the safe and stable formation of bone tissue. 
 
Cell sources 
It has been demonstrated that the regeneration of critically sized long bone defects in 
a sheep model can be improved by combining osteogenic cells and a ceramic scaffold, 
whereas the ceramic scaffold alone does not lead to uniform ossification [55]. This study 
supports the necessity of delivering viable osteogenic cells within a ceramic scaffold in order 
to achieve a stable and load-bearing osseous formation and integration. MPC isolated from 
the bone marrow are the most popular cell source to be seeded on a ceramic carrier. 
Implanted ectopically in subcutaneous pockets of nude mice, they induce bone formation 
starting from the ceramic surface [56]. Harvesting of bone marrow has to be performed under 
sterile conditions and the amount of MPC which can be isolated is age-dependent and 
limited [57]. Considering these drawbacks, attempts have been made to isolate MPC from 
alternative tissues. Dragoo et al. isolated human MPC from fat tissue and from bone marrow 
aspirates and compared the osteogenic potential of both cell sources when transfected with 
adenovirus containing BMP-2 [58]. Fat tissue-derived transfected MPC showed faster 
osteogenic differentiation as compared with MPC extracted from bone marrow. The 
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periosteum from the jaws can easily be harvested under local anesthesia and in an 
outpatient environment. Schantz and associates demonstrated in vitro osteogenic 
differentiation of periosteum derived osteoprogenitor cells and ectopic in vivo bone formation 
using a nude mouse model [59]. Recently, Schimming and Schmelzeisen reported the 
clinical use of periosteal cells in combination with a polymer fleece in the context of the 
maxillary sinus elevation procedure [60]. In a series of 27 patients, 18 showed bone 
formation 6 months after operation. However, it remains unclear whether the detected bone 
was formed by periosteal cells or by the cells surrounding the defect.   
 
Three-dimensional scaffolds 
 Support of bone regeneration by osteoconductive materials is a procedure which has 
been used in surgery for decades to restore parts of the facial skeleton. Due to excellent 
vascularization of the head and neck, incorporation of these materials in general is 
uneventful and the potential risk of infection is low as compared to other sites of the body. 
Osteoconductive materials are biomaterials which support adhesion, proliferation and 
differentiation of osteogenic cells from surrounding tissues, ultimately leading to bone tissue 
formation [61]. After an ideal time frame of a few months, the scaffold should be replaced by 
newly formed bone, undergoing subsequent integration and remodelling. Apart from animal 
or human bone-derived scaffolds, two main groups of synthetically manufactured 
osteoconductive materials can be identified: the ceramics and the synthetic polymers. The 
main differences between these materials are their ability to induce differentiation of cells, 
their rate of resorption and the possibility to apply rapid prototyping techniques in order to 
fully control the architecture and the outer design of the scaffold. Ceramics are well known to 
induce differentiation of potentially osteogenic cells towards the osteogenic lineage [62-67] 
and they are able to bridge large bony defects in human if combined with MPC [68]. Even if it 
seems to be possible to design a standardized hydroxyapatite ceramic scaffold with the help 
of rapid prototyping techniques [69], the architecture of a given scaffold (i.e., the size and the 
interconnectivity of the pores) as well as the mechanical properties can be controlled much 
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better using synthetic polymers [70]. The ability of synthetic polymers to induce osteogenic 
cell differentiation is on the other hand generally lower than that of ceramics, unless growth 
factors are incorporated and released in a controlled fashion [71].  
 
Growth factors 
Urist first popularized the concept of a bone-generating protein in 1965 when he made the 
discovery of bone morphogenetic proteins (BMP) [72]. The BMP family includes the most 
commonly used molecules for musculoskeletal tissue regeneration applications.  
In principle, three different concepts for the use of growth factors are envisioned in bone 
tissue engineering: (i) A specific growth factor can be applied during culture of osteogenic 
cells, to enhance proliferation and/or to differentiate cells [73]. After expansion, these cells 
can be combined with an osteoconductive scaffold to generate an osteoinductive graft. (ii) 
The desired growth factor may be injected directly at the site together with an 
osteoconductive material, aiming at recruitment and differentiation of MPC localised in the 
neighbouring original bone or muscle tissue [74]. (iii) Specific growth factors could also be 
incorporated within a polymer scaffold which, by degradation, will release the factor with 
defined kinetics [75].  
Vascularization and integration 
 
Due to excellent vascularization of the head and neck area, even large segmental defects of 
the jaws can be reconstructed by the use of free non vascularized bone grafts [76]. This 
favourable situation would also allow the use of large engineered grafts for the reconstruction 
of jaws, minimizing the potential risk of failing integration. In case of insufficient 
vascularization of the recipient bed, the formation of new blood vessels bringing nutrients to 
the engineered graft could be promoted by (i) the delivery of angiogenic factors, (ii) the 
generation of artificial micro-vascular networks, or (iii) the prefabrication of flaps. The use of 
angiogenic factors is gaining increasing attention by the scientific community, but requires 
definition and control of appropriate timing and dose of the specific factors. Indeed, it has 
been recently demonstrated that a long-term continuous delivery of Vascular Endothelial 
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Growth Factor (VEGF) by transfected myoblasts leads to normal vascularization, whereas 
myoblasts with high expression of VEGF induce hemangiomas [77]. The generation of micro-
vascular networks by the insertion of a vascular pedicle into the engineered tissue, buried 
subcutaneously, is an interesting innovative strategy, which is currently being explored in a 
variety of models [78;79]. The prefabrication of a flap in combination with engineered 
osteoinductive grafts has been recently described for the reconstruction of an almost entire 
lower jaw using bovine bone-derived ceramic, BMP-2 and MPC harvested from the bone 
marrow [80]. After designing the jaw with the help of 3D imaging, these components were 
implanted subcutaneously in the back of the patient and 6 weeks later the graft was 
transferred microsurgically together with the latissimus dorsi muscle. At a first glance it 
seems appealing to transfer the engineered graft together with an excellent vascularized 
muscle. However, taken into account that the harvesting procedure of the latissimus dorsi 
muscle may cause considerable donor site morbidity, the advantages of the above described 
procedure are questionable.  
In the head and neck area, stable osteosynthesis allows free vascularized bone grafts as 
well as engineered grafts to integrate under unloaded conditions. Despite stable and load 
bearing osteosynthesis in the mandible, the bony integration of an engineered graft of the 
lower jaw may require more time as compared to other unloaded bony structures of the head 
[81]. Due to pattern-dependent functional deformation of the mandible during mandibular 
movements, interfragmentary motion may occur between the original jaw and the graft, which 
may prevent efficient and rapid integration of the graft.  
 
Advances for clinical application and future horizons 
In this paper we have reviewed some of the techniques that are being developed to 
manipulate human chondrocytes and MPC to generate cartilaginous and osteoinductive 
tissues. Considering that engineered cartilage and bone tissues in reconstructive surgery of 
the head and neck would have to restore form and function, the main challenges in the future 
will be related to improve methods allowing to define the shape and stage of development of 
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the engineered tissues. Moreover, since the clinical use of engineered tissues in facial 
reconstructive surgery is so far anecdotal, critical will also be to identify which surgical 
procedures will first benefit from the advances in tissue engineering.  
Cartilage grafts for nasal reconstructive surgery will be probably the first application in 
the clinics, as these grafts have to be fairly small and after implantation would be embedded 
in a well vascularized bed. Furthermore, the nose is not subjected to high mechanical 
stresses directly after implantation of a graft and therefore the graft has to have only a certain 
amount of structural support, but does not need to be fully stable. Similar considerations are 
valid for reconstruction of the eyelids. Instead, the clinical use of engineered ear cartilage 
grafts is expected to be more complex, as in most clinical situations there is the need to 
reconstruct a soft tissue defect next to the cartilage defect. Furthermore, ear cartilage has a 
more complex anatomical shape, and the engineered ear cartilage may need to be created 
by computer-aided designed templates. An important issue for the clinical use of engineered 
cartilage in facial and reconstructive surgery will be to identify the structural and functional 
properties of the tissue engineered grafts, which need to be matched for the efficacy and 
safety of the implantation.  
The reconstruction of bone defects in the head and neck region by engineered grafts 
is already close to clinical applications. One of the main problems in bone tissue engineering 
is to induce rapid vascularization when a certain size of the constructs is reached. As the 
engineering of a vascular tissue is not yet achievable, the combination of tissue engineering 
techniques with flap surgery could bridge this gap and lead to the clinical application of 
engineered bone in facial reconstruction. Furthermore, imaging techniques combined with 
computational modeling and fabrication of scaffolds through rapid prototyping techniques are 
likely to play an important role, as the facial bones have complex 3D structures. 
One major challenge for the routine clinical use of engineered tissues is related to the 
manufacturing process, which at present is costly, impractical and not sufficiently 
standardized. In this context, we envision that 3D tissues could be engineered within closed 
bioreactor units, with advanced control systems which would facilitate streamlining and 
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automation of the numerous labor-intensive steps. Starting from a patient’s tissue biopsy, a 
bioreactor system could isolate, expand, seed on a scaffold, and differentiate specific cell 
types, thereby performing the different processing phases within a single closed and 
automated system. Such bioreactor would enable competent hospitals and clinics to carry 
out autologous tissue engineering for their own patients, eliminating logistical issues of 
transferring specimens between locations. This would also eliminate the need for large and 
expensive GMP tissue engineering facilities and minimize operator handling, with the final 
result of reducing the cost of tissue engineered products for the Health System and for the 
community. Altogether, when efficiently designed for low-cost operation, novel bioreactor 
systems could thus facilitate spreading novel and powerful cell-based tissue engineering 
approaches, which would otherwise remain confined within the context of academic studies 
or restricted to elite social classes or systems [49]. 
 





State of the art surgical reconstruction of the ala of the nose. a) Defect after tumor resection. 
b) Mucosal flap for innerlining. c) Harvested autologous graft from septal cartilage. d) Graft 
fixed in place. e) Result 4 months after reconstruction. 
 
Figure 2 
Reconstruction of a whole upper jaw by preformed fibular graft. a) Reconstruction plan on a 
plaster model, customized gauge in titanium, prepared for the first stage procedure. b) 
Drilling template used during the second stage procedure to perform the planned 
osteotomies. c) Osteotomized fibular graft, with bar reconstruction fixed on already 
osseointegrated dental implants. d) Transferred fibular graft fixed to the facial skeleton by 
miniplates, immediately after the second stage procedure. 
 
Figure 3 
Use of autologous bone chips and osteoconductive material in maxillofacial bone 
regeneration procedures. a) Split crest of upper jaw with simultaneous placement of dental 
implants, and remaining gaps filled with autologous bone chips. b) Regenerated area 
covered with a semipermeable membrane. c) Sinus elevation procedure together with 
simultaneous placement of a single implant; indicated are the mobilized and elevated sinus 
membrane (long arrow), and the newly formed space filled with osteoconductive material 
(short arrow)  
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Figure 4 
Severe defect of right anterior skull and malar complex. a) Three dimensional CT scan. b) 
Stereolithographic three-dimensional model of the facial skeleton, showing the complex 
defect and used to define the shape of the needed graft. 
 
Figure 5. 
Phases involved in an envisioned procedure of engineered cartilage for reconstruction of the 
ala of the nose. a) A smal biopsy in the nasal septum is harvested and used to isolate and 
expand autologous chondrocytes. b) Cells are then seeded into a scaffold to generate a 
tissue of predefined size and shape, which after implantation would further develop, remodel 
and integrate with surrounding tissues. 
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